Comorbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma

Table 2 Demographic, clinical, and laboratory data of patients at baseline (mean ± SD) n (%)

Variable	Perihilar (n = 37)	Distal (n = 31)	Total (n = 68)
Age (yr)	74.2 ± 10.5	72.4 ± 12.6	73.4 ± 11.5
Sex (M/F)	18/19	16/15	34/34
Smoking	13 (35.1)	8 (25.8)	21 (30.9)
Predisposing factor	5 (13.5)	1 (3.2)	6 (8.8)
Family history of malignancy	1 (2.7)	4 (12.9)	5 (7.4)
Clinical manifestations
Jaundice	33 (89.2)	26 (83.9)	59 (86.8)
Abdominal pain	16 (43.2)	9 (29.0)	25 (36.7)
Weight loss	11 (29.7)	8 (25.8)	19 (27.9)
Fever	0 (0)	3 (9.7)	3 (4.4)
Casual diagnosis	0 (0)	1 (3.2)	1 (1.5)
Symptoms duration (mo) [median (range)]	0.3 (0.01-12)	0.5 (0.05-3.5)	0.5 (0.01-12)
AST (IU/L)	146 ± 104	129 ± 121	138 ± 111
ALT (IU/L)	211 ± 166	172 ± 139	193 ± 144
γ-GT (IU/L)	629 ± 377	811 ± 660	712 ± 529
LDH (IU/L)a	269 ± 180	169 ± 54	223 ± 174
Albumin (g/dL)	3.3 ± 0.4	3.2 ± 0.7	3.2 ± 0.6
Bilirubin (mg/dL)	15.6 ± 9.1	12.6 ± 9.5	14.2 ± 9.3
Hemoglobin (g/dL)	13.4 ± 1.4	12.7 ± 2.3	13.1 ± 1.9
Platelets (× 1000/μL)	257 ± 99	294 ± 103	274 ± 102
Creatinine (mg/dL)	0.8 ± 0.4	0.8 ± 0.3	0.8 ± 0.3
CA 19-9 (IU/L) [median (range)]1	989 (2.9-65 920)	87.6 (9-11 641)	269 (2.9-65 920)

¹Data available for 29 patients;

^aP = 0.005; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CA 19-9: Carbohydrate antigen 19-9; γ-GT: γ-glutamyltranspeptidase; LDH: Lactate dehydrogenase.